Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05249387
Other study ID # N-20190062 5th project
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 11, 2022
Est. completion date October 30, 2022

Study information

Verified date September 2023
Source Aalborg University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

With this experiment, the experimenter wish evaluate the role of TRPA1 on non-histaminergic itch induced by BAM8-22


Description:

With this experiment, the experimenter wish evaluate the role of TRPA1 on non-histaminergic itch induced by BAM8-22 2 (Bovine Adrenal Medulla), which is found naturally in the human body and which has proved to evoke itch. To evaluate the role of TRPA1 it will be used a TRPA1 antagonist (A-967079)


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date October 30, 2022
Est. primary completion date May 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Healthy men and women - 18-60 years - Speak and understand English Exclusion Criteria: - Pregnancy or lactation - Drug addiction defined as any use of cannabis, opioids or other drugs - Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.) - Moles, wounds, scars or tattoos in the area to be treated or tested - Lack of ability to cooperate • - Current use of medications that may affect the trial such as antihistamines and pain killers. - Skin diseases - Consumption of alcohol or painkillers 24 hours before the study days and between these - Acute or chronic pain • - Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
A-967079 and BAM8-22 application
A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
A-967079 and BAM8-22 application after 5 minutes.
A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
A-967079 application.
A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
Vehicle and BAM8-22 application.
Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

Locations

Country Name City State
Denmark Giulia Erica Aliotta Aalborg

Sponsors (1)

Lead Sponsor Collaborator
Aalborg University

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary superficial blood perfusion is measured by a speckle contrast imager (FLPI, Moor Instruments, England) change from baseline, up to 10 minutes after the application
Primary Warm Detection Threshold, and Heat Pain threshold he tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device change from baseline, up to 10 minutes after the application
Primary Cold Detection Threshold and Cold Pain threshold the tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device change from baseline, up to 10 minutes after the application
Primary Pain supra-threshold heat Stimuli the tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device change from baseline, up to 10 minutes after the application
Primary Alloknesis s measured by using a mildy pruritic, non-painful von Frey filaments of a predetermined intensity (generally 5-30 milliNewton of force) change from baseline, up to 10 minutes after the application
Primary mechanical pain threshold and sensitivity is performed using a pin-prick set (Aalborg University). The set consists of 8 needles each having a diameter of 0,6 mm and different force applications change from baseline, up to 10 minutes after the application
Primary itch rating the subject will rate the itch for 10 minutes by using a visual analog scale (VAS) on a tablet. this scale goes from 0 to 100. 0 indicates "no itch" and 100 indicates "worst imaginable itch" change from baseline, up to 10 minutes after the application
Secondary pain rating the subject will rate the pain for 10 minutes by using a visual analog scale (VAS) on a tablet. this scale goes from 0 to 100. 0 indicates "no pain" and 100 indicates "worst imaginable pain" change from baseline, up to 10 minutes after the application
See also
  Status Clinical Trial Phase
Completed NCT01683552 - Aprepitant in the Management of Biological Therapies-related Severe Pruritus Phase 2
Completed NCT02075632 - Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream Phase 2
Completed NCT04515056 - Characterization of New Human Models of Non-histaminergic Itch N/A
Completed NCT04076865 - Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch N/A
Completed NCT04588532 - Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch N/A
Enrolling by invitation NCT05195177 - Testing Protocol to Efficiently Induce Itch N/A
Withdrawn NCT03943407 - Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch N/A
Completed NCT04858360 - Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens N/A
Completed NCT04635254 - The Effect of Halophyte-based Cream on Pain and Itch N/A
Not yet recruiting NCT06201715 - Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis N/A
Completed NCT06036589 - Characterization of Bovine Adrenal Medulla as a Model of Non-histaminergic Itch N/A
Completed NCT04554888 - Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor N/A
Completed NCT04387851 - Learning Mechanisms for Placebo and Nocebo Studies on Somatosensory Sensations: a Systematic Review and Meta-analysis.
Completed NCT03928223 - The Color of Itch; Itch Modification by Color Viewing
Not yet recruiting NCT06245564 - Effect of Ketamine, Amitriptyline and Their Combination on Histaminergic and Non-histaminergic Itch N/A
Completed NCT03576053 - A Mechanistic Evaluation of the Interactions Between Thermoceptive and Pruriceptive Sensory Processing N/A
Completed NCT04700007 - Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project) N/A
Terminated NCT02828787 - Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging. N/A
Not yet recruiting NCT04197440 - Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch N/A
Completed NCT04115462 - A Relation of Morphine-induced Itch and Pain Processing N/A